FDA dips its toe in­to the world of pa­tient-re­port­ed out­comes for can­cer tri­als

While ac­knowl­edg­ing the chal­lenge of en­sur­ing pa­tient-re­port­ed out­come (PRO) da­ta in can­cer drug ap­pli­ca­tions are con­sis­tent and of high qual­i­ty, the FDA on Wednes­day out­lined …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER